WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today presented interim results from an ongoing Phase I dose-escalation study of its oncology product candidate OXi4503 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA. Separately, OXiGENE indicated that results from mechanism-of-action studies involving OXi4503 were published on the website of Chemical Research in Toxicology in advance of the journal’s print version. (See http://pubs.acs.org/journals/crtoec/index.html.) OXi4503 (combretastatin A1 phosphate) is a dual-mechanism vascular disrupting agent (VDA) that OXiGENE is developing as a second-generation, follow-on to its lead VDA product candidate, ZYBRESTAT™, which is currently being evaluated in a pivotal registration study in anaplastic thyroid cancer under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA).
